Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439681 | 1.00 | DPP4 (0.44) | DPP4SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL805983 | 0.88 | DPP4 (0.35) | DPP4 | |
| SCHEMBL16437790 | 0.88 | DPP4 (0.39) | DPP4 | |
| SCHEMBL14478243 | 0.87 | DPP4 (0.41) | DPP4SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL13173829 | 0.81 | DPP4 (0.38) | DPP4 | |
| SCHEMBL14478269 | 0.80 | TAAR1 (0.37) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL14478259 | 0.80 | TAAR1 (0.37) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL14478251 | 0.77 | SLC6A2 (0.46) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL25946401 | 0.77 | DPP4 (0.39) | DPP4SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL14478295 | 0.77 | SLC6A2 (0.46) | SLC6A2TAAR1MAOASLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 733 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042509-B2 | Prekallikrein-modulating compositions and methods of use thereof | ADARX PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4400171-A2 | USE OF VALBENAZINE FOR TREATING SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240228434-A1 | PRODRUGS OF KV7 CHANNEL OPENERS | CHATHAM BIOPHARMA CONSULTING, LLC | 2024-07-11 | — | — | US | disclosed |
| US-20240208896-A1 | PRODRUGS OF KV7 CHANNEL OPENERS | CHATHAM BIOPHARMA CONSULTING, LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240207247-A1 | METHODS FOR THE COMBINED ADMINISTRATION OF DEUTETRABENAZINE AND A CYP2D6 INHIBITOR | NEUROCRINE BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240197714-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | NEUROCRINE BIOSCIENCES, INC. | 2024-06-20 | — | — | US | disclosed |
| EP-4384268-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | Curadev Pharma Pvt. Ltd. (IN) | 2024-06-19 | — | — | EP | disclosed |
| EP-4384169-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE | Arena Pharmaceuticals, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4384267-A1 | SMALL MOLECULE STING ANTAGONISTS | Curadev Pharma Pvt. Ltd. (IN) | 2024-06-19 | — | — | EP | disclosed |
| US-4171431-A | Nucleosides and process | THE UPJOHN COMPANY (US) | 1979-10-16 | — | — | US | disclosed |
| US-4161610-A | Process for preparing vinyl esters | UNION OIL COMPANY OF CALIFORNIA (US) | 1979-07-17 | — | — | US | disclosed |
| US-4113858-A | POLYPEPTIDES, MULTIPLE SCLEROSIS | ST. LUKE'S HOSPITAL (US) | 1978-09-12 | — | — | US | disclosed |
| US-RE29558-E | Lincomycin analogs | THE UPJOHN COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
| US-4057575-A | GROUP 8 METAL AND REDOX AGENT CATALYST | UNION OIL COMPANY OF CALIFORNIA (US) | 1977-11-08 | — | — | US | disclosed |
| US-4038478-A | ANTIBACTERIAL AGENTS | THE UPJOHN COMPANY (US) | 1977-07-26 | — | — | US | disclosed |
| US-4031304-A | Process for preparing lincomycin derivatives | THE UPJOHN COMPANY (US) | 1977-06-21 | — | — | US | disclosed |
| US-4004029-A | BENZAMIDES | THE UPJOHN COMPANY (US) | 1977-01-18 | — | — | US | disclosed |
| US-3996205-A | BACTERICIDES | THE UPJOHN COMPANY (US) | 1976-12-07 | — | — | US | disclosed |
| US-3984393-A | BACTERICIDES | THE UPJOHN COMPANY (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207247-A1 | METHODS FOR THE COMBINED ADMINISTRATION OF DEUTETRABENAZINE AND A CYP2D6 INHIBITOR | CYP2D6, CYP2B6, SLC18A2 | DPP4 596/4885SLC6A2 4/4885TAAR1 917/4885 |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | GUSB, SI, ENGASE | DPP4 81/4885SLC6A2 638/4885TAAR1 4682/4885 |
| US-20240208896-A1 | PRODRUGS OF KV7 CHANNEL OPENERS | KCNA7, KCNB1, KCNB2 | DPP4 2178/4885SLC6A2 1018/4885TAAR1 995/4885 |
| US-20240228434-A1 | PRODRUGS OF KV7 CHANNEL OPENERS | KCNA7, KCNB1, KCNB2 | DPP4 2178/4885SLC6A2 1018/4885TAAR1 995/4885 |
| US-20240197714-A1 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | DPP4 1211/4885SLC6A2 2/4885TAAR1 450/4885 |
| US-12042509-B2 | Prekallikrein-modulating compositions and methods of use thereof | KLKB1, PRKG1, PRKCH | DPP4 2992/4885SLC6A2 3115/4885TAAR1 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.